The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > September 7, 2021
Daily News
September 7, 2021
- Nichi-Iko’s Medipal Tie-Up Stirring Concerns over Generic Trades, Price Gyrations
September 7, 2021
- Japan Strikes Deal for 150 Million Novavax Vaccine Doses, Supply Could Start Early Next Year
September 7, 2021
- Astellas’ Padcev, Pfizer’s JAK Inhibitor, AZ’s Lupus Drug Clear PAFSC Panel
September 7, 2021
- Keytruda Top-Selling Drug in Japan in August: Encise
September 7, 2021
- Takeda Faces New Problem on Leuplin, System Glitch Cripples Supply of 1, 3-Month Products
September 7, 2021
- Pfizer Vaccine Imports Set to Be Completed in October: Minister
September 7, 2021
- MHLW Panel Backs Takeda’s Cell Therapy Darvadstrocel for Complex Anal Fistulas in CD
September 7, 2021
- Drug Makers Should Conduct Joint Inspections at Contract Manufacturers to Prevent GMP Violations: Expert
September 7, 2021
- GSK Files COVID-19 Antibody Drug Sotrovimab in Japan
September 7, 2021
- Roche Diagnostics Launches EZH2 Mutations Test for Eisai’s Tazverik in Japan
September 7, 2021
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…